Background. Several new medications for type 2 diabetes (T2DM) have been introduced, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor (GLP-1) agonists. Variation in the prescribing of these agents has implications for quality, safety and costs. We aimed to investigate geographical variation in the prescribing of anti-diabetic medications in Ireland. Methods. Cross-sectional analyses were undertaken on the two main national pharmacy claims databases in Ireland in 2013 and 2014. Direct standardized rates of individual anti-diabetic medication prescribing per 100 000 population were calculated by geographical area. Variation in prescribing was assessed using the systematic component of variation (SCV) and classified as very high (>10), high (5.4-10), moderate (3-5.4) or low (<3). Estimated total costs of prescribing were calculated per geographical area using medication wholesale costs.
Introduction
Globally, type 2 diabetes mellitus (T2DM) is rising in prevalence with a substantial burden on both patients and society (1) (2) (3) . The complications of T2DM can be largely prevented with adequate glycaemic and cardiovascular risk factor management (3, 4) . This has been supported in the past decade with the arrival of new classes of anti-diabetic medications, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor (GLP-1) agonists. DPP-4 inhibitors and GLP-1 agonists are recommended as second-or third-line agents, especially in certain patient populations, such as those with insulin resistance and an increased body mass index (BMI) (4) . It has been shown that newer agents demonstrate similar effectiveness to one another and concerns have been expressed regarding their safety, including the possibility of an increased risk of pancreatitis with GLP-1 agonists and heart failure admissions with DPP-4 inhibitors (5-7). Furthermore, newer anti-diabetic agents are more expensive and GLP-1 agonists can only be administered by subcutaneous injection. In the UK in 2014, sitaglipin, a DPP-4 inhibitor, was the leading drug in terms of net ingredient cost, followed by liragultide, a GLP-1 agonist (which had the highest cost per item at £101.25) (8) . In 2014, the Irish State spent €9.1 million on DPP-4 inhibitors (225 000 prescriptions), €12.1 million on GLP-1 agonists (75 000 prescriptions), but only €3.2 million on sulphonylureas (512 000 prescriptions) and €4.7 on metformin (1 million prescriptions) (9) . Therefore, variation in the prescribing of these medications has implications on quality, safety and health care costs.
Variation in health care has been reported since 1938, when Glover found a 20-fold difference in tonsillectomy rates across London boroughs (10) . This field of study has been developed further since the 1980s with studies outlining many variations in the processes of health care (2, 10) . Whilst variations in health care can be warranted and reflect the differences in health care needs across different populations, research has suggested that significant unwarranted variation in health care exists (2, 11) . Indeed where an intervention is effective, there should be little or no variation in clinical practice (10) . Overall, three major sources for unwarranted variation in health care have been identified by Wennberg (2) . The first is called variation in 'effective care', which typically manifests through an underuse of a treatment by a physician or a failure to adopt and implement evidence-based guidance (2, 11) . The second type of variation occurs where there is more than one treatment option available for patients. Here, variation can occur on account of both professional opinion and patient choice and is called variation in 'preference sensitive care' (2). The last form of variation in clinical activity can occur based on differences in the capacity of the health care system (e.g. accessibility of services) and is called variation in 'supplysensitive care' (2) . As an example of variation in medical procedures, in the USA, adjusted rates of arthritic knee replacement have been shown to vary by a factor of 4.7, hip replacement by 5.3 and mastectomy for breast cancer by 7.3 (2). In the UK, hip replacement rates have shown a 4-fold variation (10) . In terms of diabetes care, unwarranted variation in the quality care has been demonstrated in the Dartmouth Health Atlas with no association between higher drug spending on markers of quality or improved patient outcomes for diabetes (12) . Much of the literature on variation to date has focused on variation in hospital-related procedures, but there are some data on variation in the prescribing of diabetes medications in the USA and UK (2, 8, 10, (12) (13) (14) (15) . The first step to address unwarranted variation in health care is the systematic, routine collation and publication of data on such variations (10) . In Ireland, there is limited information on geographical variation in prescribing, particularly for T2DM.
Our aim was to examine the extent of geographical variation in the prescribing of anti-diabetic medications in Ireland, with a focus on newer, more costly agents. Our secondary aims were to investigate the impact of identified variation on estimated drug costs and to explore potential causes for any variation identified.
Methods
A cross-sectional analysis was performed on the two national community-based pharmacy claims databases in the Republic of Ireland (RoI) in 2013 and 2014, identifying repeat dispensing of metformin, sulphonylureas, DPP-4 inhibitors and GLP-1 agonists using WHO ATC Codes (ATC A10B). Box 1 outlines the structures of the dispensing databases and the existing models of T2DM care in the RoI. We defined repeat dispensing as three consecutive items dispensed per year. Combination drugs were included. Overall prescribing rates in these datasets were analysed by geographical area, reflecting the 32 Local Health Offices (LHOs) represented in the pharmacy claims datasets. The 2011 Central Statistics Office (CSO) data were used for standardization by age and gender as no projected data by LHO for 2013 and 2014 was available (www.cso.ie). CSO data are divided into 34 geographical areas, which do not overlap exactly with the 32 LHOs identified in the pharmacy claims database. In total, 19 geographical areas were created for the analysis by matching the CSO and the pharmacy claims database geographical areas. Directly standardized rates per 100 000 adult (>30 years of age) Irish population were calculated using the European Standard population. To benchmark the Irish prescribing data, we compared 2014 non-standardized absolute prescribing rates (items dispensed annually/national population) of anti-diabetic agents with English data, using the Irish pharmacy claims databases, open-prescribing data on NHS England (https://openprescribing.net) and Irish and English statistics registries (www.cso.ie ; www.ons.gov.uk).
Box 1. Prescribing databases and models of structured type 2 diabetes mellitus care in the Republic of Ireland

Prescribing databases in Ireland
• The General Medical Services (GMS) scheme provides medical care to ~40% of the Irish population. It is predominantly means-tested and provides those who are eligible with free general practitioner visits, free hospital care and free medications (except for a prescription levy, currently €2.50 per item to a maximum of €25).
• The Long Term Illness (LTI) Scheme allows persons with certain medical conditions (T2DM being one) to have free access to medications which treat that condition.
• The GMS and LTI schemes are administered by the Health Services Executive (HSE) and Primary Care Reimbursement Services (PCRS).
• Combined, the GMS and LTI prescribing-claims databases capture almost all dispensing for patients with T2DM in the Republic of Ireland.
Structure of diabetes care in Republic of Ireland
• Before October 2015, structured chronic disease management of T2DM was not universally available in Irish primary care. Approximately 10 primary care schemes existed in 2013 and 2014, providing different levels of structured T2DM care, often set up as pilot schemes. This represented a maximum of 250 practices within Irish general practice (~10% of total practices).
• Up until October 2015, the vast majority of structured T2DM care in Ireland was provided in secondary care, through public hospital outpatients or under the care of endocrinologists in private clinics.
• In October 2015, a new agreement was reached with GPs entitling all GMS patients to a structured diabetes programme in primary care (called a Diabetes Cycle of Care) with two free GP visits per annum.
Variation in standardized prescribing was measured using the systematic component of variance (SCV) which represents the systematic variation considered to be beyond chance:
where k is the number geographical units, O i is the observed standardized prescribing rate and E i is the expected standardized prescribing rate (16) . Typically, the SCV statistic uses the K values between the 5th and 95th percentile to reduce random noise (16) . The larger the SCV value, the higher the variability; SCVs greater than 10 suggests very high variation; high variation is represented by an SCV between 5.4 and 10.0; SCVs >3, but <5.4, represent moderate variation and are likely to be due to differences in practice style or medical discretion; SCVs less than 3 are considered low variation (17).
Where we identified variation in prescribing, possible associations were considered using measurable variables, reflecting effective care, supply-sensitive care and preference sensitive care. The potential causes of variation are complex, ranging from patient preferences to the nature of funding of health care (10) . We were only able to include one variable that reflects variation in supply-sensitive care, which was the location and number of diabetes specialists in the RoI, using the Irish Medical Directory (18) . Standardized prescribing rates were compared to the crude number of diabetes specialists per geographical area, using Spearman rank correlations. Other data relating to supply-sensitive care such as location of primary care practitioners as the data were not available in appropriate formats. We were also unable to identify Irish data sources for other variables that might explain variation in effective or preference-sensitive care. Estimated total costs of medications were assessed for geographical area, using the standardized prescribing rates and the wholesale cost of medicines, using the most commonly prescribed medication and dose in each class, derived from an Irish medication formulary (19) .
Results
Overall, the number of patients using anti-diabetic agents increased from 2013 to 2014; 86 668 and 98 328 for metformin (14% relative increase), 47 299 and 51 833 for sulphonylureas (10% increase), 27 274 and 34 939 for DPP-4 inhibitors (28% increase), and 6297 and 7665 for GLP-1 agonists (22% increase), respectively.
The absolute prescribing rates of metformin alone and sulphonylureas were higher in England than in Ireland. Conversely, GLP-1 agonists and DPP-4 inhibitors (that included metformin combinations) were higher in Ireland (Supplementary Data S1).
Standardized prescribing rates by geographical area
Very high levels of geographical variation in the standardized prescribing of GLP-1 agonists were present in 2013 and 2014 (in the 19 local areas) with an SCV of >10 (Table 1 ). The SCV was >3, but <5.4, for DPP-4 inhibitors when the highest and lowest prescribing counties were excluded. There was no evidence of geographical variation for metformin prescribing and low to moderate sulphonylurea prescribing in 2013 and 2014, respectively (Table 1) . Figure 1 highlights the prescribing variation for each anti-diabetic medication in both 2013 and 2014, comparing the standardized prescribing rate for each geographical area to the mean rate for that medication. It shows greater geographical variation in the prescribing of GLP-1 agonists and DPP-4 inhibitors, compared to metformin and sulphonylureas. Figure 2 shows the standardized prescribing rates of all anti-diabetic medications for 2014. Supplementary Data S2 shows the standardized prescribing rates of DPP-4 inhibitors and GLP-1 agonists for 2013 and 2014.
There was a male:female difference in standardized prescribing rate for each medication in 2013 and 2014, reflecting the different prevalence in T2DM between genders, with prescribing for males being consistently higher for all agents than females (20) .
Potential sources of variation
The crude number of diabetes specialists per geographical area was not associated with geographical variation in standardized prescribing rates of anti-diabetic medications (Supplementary Data S3). We were unable to access appropriate data to examine other potential sources of variation.
Estimated costs of variation
We estimated the direct costs of the geographical variation in standardized prescribing for the variation in GLP-1 agonists (see Supplementary Data S4). In 2014, the cost of GLP-1 agonist prescribing per 100 000 standardized population varied from €170 609 in Clare (the lowest rate) to €709 540 and €691 112 in Longford/ Westmeath and Waterford, respectively (the highest prescribing areas). Variation in the standardized prescribing rates, between the nineteen geographical areas, were compared using the systematic component of variation (excluding the highest and lowest prescribing regions) and a ratio of the highest to lowest prescribing areas.
Conclusion
Summary of findings
The use of all anti-diabetic drugs increased from 2013 to 2014, reflecting rising prevalence rates (20) . Very high geographical variation in GLP-1 agonist prescribing was found in cross-sectional analyses in 2013 and 2014 in Ireland. Moderate variation in DPP-4 inhibitor prescribing was also found. Prescribing of older, wellestablished oral hypoglycaemic agents shows less variation in prescribing across geographical areas, with metformin showing low and sulphonylureas low/moderate variation. Newer anti-diabetic agents are more expensive and the identified prescribing variation has cost implications for patients and the health care system. Ascertaining variation is the first step in addressing unwarranted variation, followed by assessment of potential causes; however, we were unable to definitively identify a cause of this variation (10) . We hypothesize that differences in both effective care and preference sensitive care may be implicated.
Strengths and limitations
A strength of this study is that it is population-based, including almost all individuals who are in receipt of the anti-diabetic medicines in Ireland. Although based on administrative claims data, it captures all prescribing in a very large population, with information on the age, gender and location of the individuals. High levels of variation of GLP-1 agonist prescribing in Ireland should be contextualized with the low overall absolute prescribing of these agents in both 2013 and 2014 in the RoI (Fig. 1) . The absolute prescribing rates of anti-diabetic agents in 2014 in England and Ireland are nonstandardized (Supplementary Data S1) and cannot be used to infer appropriateness of prescribing, given the underlying differences in population demographics, which may explain these differences.
Our analysis was ecological in nature and not linked to specific practices or prescribers, so we were unable to assess the impact that the variation in prescribing has on patient outcomes which would be beneficial for future policy makers to monitor variation in processes of diabetes care (21) . This also limited our ability to address our secondary aims including identification of the sources of variation. To assess variation in supply-sensitive care, we examined the numbers and locations of diabetes specialists in the RoI, but the referral catchment areas for endocrinologists are uncertain and do not overlap with the prescribing geographical areas and numbers of specialists are small. We were unable to investigate the effects of specific remunerated primary care schemes on variation, as they did not fit within the geographical areas we defined. However, these schemes only covered a small proportion of primary care populations in Ireland during the time frame of this study (<10%). In 2013 and 2014, outside of these primary care schemes, Irish GPs were not resourced to provide structured management of T2DM, so there was significant variation in primary diabetes care. Whilst some practices did engage in management of their patients, the majority of T2DM care took place in the secondary care setting (Box 1). During this time period, most Irish GPs would have prescribed first line agents for T2DM (e.g. metformin), but it is unlikely that they would have routinely commenced second or third line agents (e.g. GLP-1 agonists) in the absence of a contract for providing care for these patients and given clinical guidelines at that time suggested specialist referral for those with poorly controlled T2DM. Data on community diabetic specialist nurses, also reflecting supply-sensitive care, were not available, but only a very small number of diabetic specialist nurses were operating in the community in 2013 and 2014, mostly within the small number of structured schemes. We were unable to use measurable comparative variables, as markers of effective or preference-sensitive care, such as payments to doctors from pharmaceutical companies and uptake in postgraduate education. Our cost analysis was an estimate based upon the wholesale pharmaceutical prices of the most commonly prescribed medication and dose in each class. We did not assess the actual costs of medication prescribing and we did not look at indirect costs. The cost of medications can differ depending on the prescribing scheme and our estimates assume 100% adherence to each medication over 1 year, although the data are based on dispensed medicines which will have incurred cost whether the patients are adherent or not. We may have, therefore, under-or overestimated the true cost differentials, based upon the observed variation in prescribing.
Comparison with existing literature
Unwarranted variation in medical practice has been demonstrated within and between countries (11, 12, 15, 22) . In the UK, the NHS Atlas of Variation, which includes data from 152 primary care trusts and 34 geographical areas, has shown unwarranted variation in the percentage of people with diabetes receiving nine key care processes, such as blood glucose, urine and foot checks (14) . A 3-fold variation in the prescribing of non-insulin anti-diabetic drugs has been demonstrated in the UK, with higher spending not associated with better glycaemic control (15) . English primary care trusts exhibit a 1.5-fold variation in the number of persons meeting target blood pressure (BP) levels (range 40-60%) (15) . International standardized prescribing rates for medications are not widely available, but the absolute prescribing rates of GLP-1 agonists and DPP-4 inhibitors was slightly higher in Ireland than England, with a lower rate of prescribing of metformin and sulphonylureas (Supplementary Data S1). Inter-country variation in glucose-lowering medication prescribing in Portugal and the Netherlands between 2004 and 2013 has also been studied (23) . Portugal had higher DPP-4 inhibitor prescribing rates, and higher overall consumption and costs relating to anti-diabetic medications compared with the Netherlands, but we cannot directly compare these results to Ireland as different standardized prescribing rates were used. Broad regional variation in the prescribing of both insulin and oral anti-diabetic agents was shown in Ireland over 2002-12, but it did not examine the geographical variation at a county level (24) . Our study explored variation in more detail and expanded the geographical areas to analyse variation throughout the RoI.
We hypothesize that the observed variation in GLP-1 agonist prescribing in Ireland relates predominantly to a combination of variation in preference sensitive and effective care (2). We do not know whether GLP-1 agonists were initiated in primary care or secondary care. However, as structured diabetes management was not universally available in Irish primary care prior to 2015, it is likely that intensification with GLP-1 agonists was generally initiated in secondary care, by diabetes specialists. Our results suggest that the numbers and locations of diabetes specialists in the RoI were not associated with variation in GLP-1 agonist and DPP-4 inhibitor prescribing, suggesting the variation is not largely being driven by 'supply-sensitive care'. Patient preference is reflected in shared decisions regarding glycaemic medications, taking account of differing personal choices regarding lifestyle options and the route of administration, e.g. GLP-1 agonists require subcutaneous injection. GLP-1 agonist variation may be 'preference sensitive' or associated with clinical inertia given the additional supports needed to educate patients in using these agents. Although second-line agents show similar efficacy, newer incretin mimetics are recommended in specific situations (e.g. GLP-1 agonists as a second-line agent with a BMI of >35 kg/m 2 ) and one should not expect widespread variation in their prescribing (4, 7) . Variation in 'effective care' may, therefore, explain some component of the variation with different application of clinical guidelines in T2DM management in Ireland in terms of GLP-1 agonist and DPP-4 inhibitor prescribing.
Implications for research
We cannot conclusively say if low-prescribing areas in the RoI relate to inappropriate levels of prescribing. In the absence of widespread standardized prescribing data of these newer agents, it is difficult to establish what the correct benchmark for prescribing of newer oral and injectable hypoglycaemic agents should be. The use of anonymized data, extracted from health records, provides an opportunity for policy makers to support and monitor integrated management of diabetes. Structured management of T2DM in Irish General Practice commenced in 2015 and its impact on geographical variation in prescribing should be analysed. Future research should look at variation in family practice-based processes of care and markers of quality (such as prescribing). This research should also assess variation at a practice level and link this to patient process outcomes, such as HbA1c, BP and lipid control. Furthermore, the pharmaceutical industry can influence physician-prescribing behaviour (25) (26) (27) , and the association with variation in care with voluntary public disclosures of health care professionals, in pharmaceutical payments (Transfers of Value to Healthcare Professionals and Healthcare Organisations in Ireland https://www.transferofvalue.ie), should be explored further.
Conclusion
Very high levels of GLP-1 agonist prescribing variation existed in 2013 and 2014, in Ireland, with moderate variation of DPP-4 inhibitors. This prescribing variation should be considered in the context of a 22-28% annual increase in the prescribing of the newer oral and injectable agents, and in the context of higher absolute levels of prescribing in Ireland compared to England of DPP-4 inhibitors and GLP-1 agonists in this time period. No obvious cause for this variation was identified, but it is likely related to variation in both effective care and preference sensitive care, with health policy implications for cost and quality of care.
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